AtaiBeckley Inc.

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company headquartered in New York, NY, with additional offices in Berlin, Germany. The company's mission is to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. It was formed in November 2025 through the strategic combination of atai Life Sciences and Beckley Psytech Limited, subsequently redomiciling from the Netherlands to the U.S. (Delaware) in December 2025.

AtaiBeckley focuses on developing therapies for mental health disorders, including those based on psychedelics, entactogens, and related compounds. Its pipeline includes several investigational compounds: BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD) and alcohol use disorder, which has received FDA Breakthrough Therapy designation and is in Phase 3 planning/development; VLS-01 (DMT buccal film) for TRD, currently in Phase 2 clinical development with plans for Phase 3 in Major Depressive Disorder; and EMP-01 ((R)-MDMA HCl) for social anxiety disorder, also in Phase 2 clinical development. The company also has other programs, including RL-007 for cognitive impairment associated with schizophrenia and ELE-101 for major depressive disorder, and is advancing a drug discovery program for non-hallucinogenic 5-HT2AR agonists.

As of July 2026, AtaiBeckley Inc. is publicly traded on the NASDAQ exchange under the ticker symbol ATAI, with a market capitalization of approximately $1.91 billion. Dr. Srinivas Rao serves as Co-Founder and Chief Executive Officer, and Michael Faerm was appointed Chief Financial Officer in March 2026. Recent developments include the completion of patient dosing in the Phase 2b clinical trial for VLS-01, with topline data anticipated in Q4 2026, and the advancement of BPL-003 into pivotal Phase 3 trials. The company joined the Russell Indexes in June 2026 and reports a cash runway extending into 2029.